We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Better Biosensors Made with Electron Density Waves

By LabMedica International staff writers
Posted on 18 Nov 2010
Print article
An emerging field called optofluidic plasmonics has the potential for a new way to detect and analyze biologic molecules for drug discovery, medical diagnostics, and the detection of biochemical weapons.

Investigators from the University of California, San Diego (UCSD; USA) led by Dr. Yeshaiahu Fainman have succeeded in merging a microfluidics system with plasmonics--also called "light on a wire”--onto a single platform. Plasmonics is based on electron waves on a metal surface excited by incoming light waves.

According to Dr. Fainman, tapping the potential of plasmonics for biomolecule detection systems has been a challenge, because localized optical field scales are usually much larger than the molecules being studied. In order to make a useful optical biosensor, he stated, "We need to increase the interaction cross-section by finding ways to localize optical interrogation fields ideally to the scales comparable to those of biomolecules.”

Since that is not currently possible, he and his team used an approach of integrating microfluidics and plasmonics on single chips, allowing fluid to transport the molecules into the cross-section of the optical field. Dr. Fainman expects the system to be especially beneficial in examining large arrays of protein-protein interactions for identifying potential drugs that bind to specific target molecules, which may lead to earlier cancer diagnoses and faster discovery of new drugs. Unlike most traditional techniques, optical detection does not require labeling of molecules with fluorescent or radioactive entities--labels frequently suppress interaction by covering up or blocking binding surfaces.

The new platform also carries the advantage of being high throughput and multiplexed, offering researchers an opportunity to examine thousands of arrayed compounds simultaneously, which Dr. Fainman concluded, "Biologists and physicians get very excited about.”

The study's findings were presentation, presented October 26, 2010, at the Frontiers in Optics (FiO) 2010/Laser Science XXVI--the 94th annual meeting of the Optical Society (OSA), which was held together with the annual meeting of the American Physical Society (APS) Division of Laser Science in Rochester, NY, USA, from October 24-28.

Related Links:
University of California, San Diego

Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Verification Panels for Assay Development & QC
Seroconversion Panels
New
RFID Inlay
Minidose U8 RAIN
New
Mumps Virus Test
ZEUS ELISA Mumps IgG Test System

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.